Case Report (n=1)
No
Highlights severe diarrhoea as a rare but reversible adverse effect of ticagrelor therapy following PCI.
Answers are grounded in this paper and cite their sources.
May represent underrecognized ticagrelor adverse effect; single case leaves open true incidence and DAPT implications.
Ticagrelor is a part of dual antiplatelet therapy (DAPT) which has proven benefits in patients with acute coronary syndrome especially in those undergoing percutaneous coronary intervention (PCI). However, like most other drugs, it can lead to undesired and adverse effects such as dyspnoea, easy bruising and gastrointestinal bleeding. We present a case of 70-year-old woman who developed diarrhoea following initiation of DAPT comprising of aspirin and ticagrelor following PCI. After excluding more common causes, it was attributed to ticagrelor administration and completely resolved after it was replaced with another oral antiplatelet agent. On follow-up, the patient reported complete resolution of symptoms.
No takes yet. Share an insight, caveat, or question.
Rashid et al. (2021) conducted a case report in Severe diarrhoea due to ticagrelor (n=1). Ticagrelor was evaluated on Resolution of severe diarrhoea.
Synapse has enriched 10 related papers. Consider them for comparative context: